Ipsen: Oddo a buyer after announcement on cabozantinib
(CercleFinance.com) - Ipsen has announced that the New England Journal of Medicine (NEJM) has published the results of the pivotal phase 3 study Celestial on cabozantinib in patients with advanced HCC that has been previously treated.
Following this announcement, Oddo confirms its buy rating on the stock, along with its target price of 133 euros.
Results suggest that, if approved, cabozantinib could become an attractive proposed treatment that could help slow the disease's progression and, more importantly, improve patient survival, the broker added.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
Following this announcement, Oddo confirms its buy rating on the stock, along with its target price of 133 euros.
Results suggest that, if approved, cabozantinib could become an attractive proposed treatment that could help slow the disease's progression and, more importantly, improve patient survival, the broker added.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.